

**FORM 51-102F3
MATERIAL CHANGE REPORT**

Item 1: Name and Address of Reporting Issuer

Sire Bioscience Inc. (the “Company”)
2500 Meadowpine Blvd, Unit 202
Mississauga, ON L5N 6C4

Item 2: Date of Material Change

January 20, 2021.

Item 3: News Release

A news release was issued and disseminated on January 20, 2021 and filed on SEDAR (www.sedar.com).

Item 4: Summary of Material Changes

The Company announced the application for a management cease trade order for late filing of annual audited financial statements. See Item 5 for full details.

Item 5: Full Description of Material Change

The Company announced that it will be unable to file its annual audited financial statements, management’s discussion and analysis and related certifications for the year ended September 30, 2020 (the “**Annual Filings**”) on or before the prescribed filing deadline, as required by National Instrument 51-102 *Continuous Disclosure Obligations*, and National Instrument 52-109 *Certification of Disclosure in Issuers’ Annual and Interim Filings*, respectively. The Company anticipates that its auditor will need approximately 3 weeks to complete the audit of the Company’s annual financial statements.

The Company has filed an application with the Ontario Securities Commission, the British Columbia Securities Commission and the Alberta Securities Commission requesting issuance of a management cease trade order against the Company’s executive officers and directors instead of a cease trade order against the Company and all of its securityholders.

The Company anticipates that it will be in a position to file the Annual Filings on or before February 15, 2021. The Company confirms that it will comply with the alternative information guidelines included in National Policy 12-203 *Management Cease Trade Orders*, for so long as it remains in default of a specified requirement.

Item 6: Reliance on subsection 7.1(2) or (3) of National Instrument 51-102

Not applicable.

Item 7: Omitted Information

None.

Item 8: Executive Officer

Brian Polla, CEO and COO
T: 416.669.9392
E: ir@sirebioscience.com

Item 9: Date of Report

January 20, 2021.